Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
For info if people haven't seen already . Good news IMO. Pbx is an access stock though, so hopefully will follow soon
July 6, 2022
Aquis Exchange PLC
(“Aquis” or the “Group”)
AQSE is delighted to announce that for the first time in the exchange’s history, APEX stocks are now available to trade electronically on the Hargreaves Lansdown trading platform, the UK’s number one platform for private investors.
As the next-generation stock exchange continually pushing to reshape capital markets, we would like to thank Hargreaves Lansdown for their support and look forward to working closely with the team there to add our ACCESS stocks in due course.
Commenting on the development, Aquis Exchange, CEO Alasdair Haynes, said:
“I am very pleased that Hargreaves Lansdown is now including certain AQSE shares for electronic trading on its platform. I know that there is much client demand for this and we are looking forward to the scheme being extended to cover many more AQSE stocks as soon as possible. It is vital for the public to be able to access the shares quoted on the UK’s two stock exchanges easily, efficiently and, crucially, on an equal footing as each other.”
Tom Lee, Head of Trading Proposition, Hargreaves Lansdown, said:
“As market leader, we continue to evolve and digitise our trading service and offering APEX stocks via an easy online experience reflects our ambitions to redefine the savings and investing experience for investors.”
AQSE is home to over 100 securities and has welcomed 11 new companies to its growth market so far this year, with many more in the pipeline. As a division of leading exchange services company, Aquis Exchange PLC, AQSE is a business underpinned by a robust regulatory framework, overseen by the FCA, and has a strong service culture.
bit more here - looks like launched c2020
https://www-39ytu-com.translate.goog/actualidad/ucam-capsa/lactobacillus-plantarum-lpldl-para-la-salud-cardiovascular/?_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en-US&_x_tr_pto=wapp
mol
not sure when launched but going by video with Oswaldo (as we know he is no longer with Optibiotix) at least three years ago (we did have Col-15-fresa previously - is this just a renaming?)
anyway
https://www-39ytu-com.translate.goog/productos/coles-pro/reducir-tu-colesterol/?_x_tr_sl=es&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
and still being promoted on their facebook page 18 July 2022
https://ms-my.facebook.com/39ytu
and here
https://diabetika-es.translate.goog/es/probioticos/1167-39ytu-coles-pro-tratamiento-15-dias--8437019061234.html?_x_tr_sl=es&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
so still generating a revenue presumably
just a bit of info
mol
Yes
sorry to state the obvious
he has been on garden leave from March and our company would have known the length of same prior to rns release
but of course we aren't adult enough presumably to be given the full picture
also note opti has noted my research re We Test You Trust in an rns today
follows up on my theislandnow post some months ago
still not paid for any of this
lol
mol
Still on garden leave apparently
https://dk.linkedin.com/in/steen-dannemann-andersen-96a3222
5 months so far - could be only another month or seven - generally a year at his level
Our company should let us know but methinks it will be March next year until his appointment confirmed
so presumably Stephen carries on until then , drawing salary etc - albeit presumably new CEO designate isn't being paid
New CEO designate - that's what the RNS should have said though didn't
wonder if this came up in interview posted today?
Question - is Steen being paid from RNS announcement ?
Shouldn't be as being paid by previous employer
Just noting this for the future
mol
mol
Completely missed that rns. It just shows what a drag it is to get things going.
Could be that the peer revue has helped push things forward.
https://www.optibiotix-ir.com/content/news/archive/2020/17-09-20
Which I had overlooked
I,m beginning to think this went nowhere as no mention in admission document
https://probiotixhealth-ir.com/corporate/admission-document
mol
Looks as though Ayalla are taking LPLDL to market/manufacturing? Did I miss the RNS?
https://ayalla.com.br/en/
which is
The Brazilian Health Regulatory Agency (Anvisa)
seemingly LPLDL under discussion for approval
https://app.swapcard.com/event/food-ingredients-south-america-2/product/UHJvZHVjdF80Njg0MTg%3D
mol
Brochure
https://nutraingredientsusa-awards.com/live/en/page/brochure
mol
Winner of probiotic of the year at nutraingredients usa 2022
Can only help sales
Links over at Opti as posted there first as a bit more life on that board
mol
Thank you. Yes, I saw conflicting info on different sites, think the other figure I saw must have been quoted in Euros as it's on a European stock exchange. Cheers.
It's above this chat if you scroll up. it's traded in GBP.
Share Price: 21.00
Bid: 20.00
Ask: 22.00
Can someone confirm what the current share price is here? Plus, is it listed in £ or Euros?
if it is the video is prior to our rns release and this company is in Puerto Rico
mol
this may be another one (there are a number of these strains)
https://m.facebook.com/vaqueriatresmonjitas/videos/yogur-bebible-probi%C3%B3tico-lactobacillus-plantarum/1038327030429276/
https://www.youtube.com/watch?v=l5kOmCzPL5I
https://www.tresmonjitas.com/yogur-bebible/
mol
for completeness
a letter of appointment between the Company and Adam Reynolds dated 31 March 2022, pursuant to which Mr Reynolds was appointed as a non-executive Director and chairman of the Company for an annual fee of £30,000, payable monthly in arrears. Mr Reynolds is required to devote such time as is necessary for the carrying out of his duties as a non-executive Director of the Company. The appointment is terminable on 3 months’ notice on either side, save that Mr Reynolds cannot terminate on notice at any time within the first 12 months of the appointment. No compensation is payable for loss of office and the appointment may be terminated immediately if, among other things, Mr Reynolds is in material breach of the terms of the appointment. The appointment letter supersedes and replaces a letter of appointment made between Mr Reynolds and ProBiotix dated 21 September 2018 as related to Mr Reynolds’ appointment as a non-executive director of ProBiotix;
6.1.4 a letter of appointment between the Company and Marco Caspani dated 31 March 2022, pursuant to which Mr Caspani was appointed as a non-executive Director of the Company for an annual fee of £20,000, payable monthly in arrears. Mr Caspani is required to devote such time as is necessary for the carrying out of his duties as a non-executive Director of
the Company. The appointment is terminable on 3 months’ notice on either side, save that Caspani cannot terminate on notice at any time within the first 12 months of the appointment. No compensation is payable for loss of office and the appointment may be terminated immediately if, among other things, Mr Caspani is in material breach of the terms of the appointment.
mol
Just an observation from admission document
The Group has entered into service agreements and letters of appointment as follows:
6.1.1 an agreement between Stephen O’Hara and ProBiotix dated 31 March 2022, pursuant to which Mr O’Hara agreed to act as Chief Executive Officer of ProBiotix on a part time basis committing a minimum of 18½ hours per week. In the absence of breach, the appointment is terminable on six months’ notice on either side. The salary payable to Mr O’Hara is £106,000 per annum. Mr O’Hara has agreed to post termination restrictions on competing activity, which commence on termination of the appointment (such that no period of gardening leave shall be counted as part of the restricted period). Mr O’Hara previously carried out duties for ProBiotix as part of shared services with OptiBiotix;
6.1.2 an agreement between Mikkel Hvid-Hansen and ProBiotix dated 31 March 2022, pursuant to which Mr Hvid-Hansen agreed to act as Commercial Director of ProBiotix. In the absence of breach, the appointment is terminable on three months’ notice on either side. The salary payable to Mr Hvid-Hansen is €175,000 per annum. Mr Hvid-Hansen has agreed
to post termination restrictions on competing activity, which commence on termination (such that no period of gardening leave shall be counted as part of the restricted period). Mr Hvid-Hansen’s continuous employment with ProBiotix commenced on 3 February 2020 (which employment was governed under a prior service agreement, as has been replaced and superseded by the 31 March 2022 agreement);
presumably our full time executive will be paid far in excess of Stephen's salary - and therefore Stephen's reduced - I await with interest - unfortunately that will take until june 2023 - 5 months after the legal ownership of PBX shares transferred
mol
Who has worked with our Commercial Director at Deerland (who purchased Bifodan in 2019)
https://gb.kompass.com/c/deerland-probiotics-enzymes-a-s/dk059564/
just a bit of info which may not have been obvious in rns releases
mol
Our Commercial Director Mikkel Hvid-Hansen
https://www.naturalpharmacybusiness.com/imag/npbjunejuly22/
mol